Delivery Order SPE2DB22D3011-SPE2DB25FQ2LL
- Not listed
- The Defense Logistics Agency awarded a $33,589.80 delivery order to AmerisourceBergen Drug Corp for 1,440 units per milliliter of HAVRIX vaccine in syringe form. This competitively awarded, firm fixed price contract was executed on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified suppliers. This delivery...
- The Defense Logistics Agency awarded a $11,463.02 delivery order to AmerisourceBergen Drug Corp for 1,440 units/mL of HAVRIX vaccine syringes on July 28, 2025, with completion targeted for July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,597.88 to AmerisourceBergen Drug Corp for 1,440 units/mL of Havrix vaccine in syringes. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, utilizes a firm fixed price structure with no set-aside designation. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $6,216.20 to AmerisourceBergen Drug Corp for 1,440 units per milliliter of HAVRIX vaccine in syringe form. This firm fixed-price, competitively awarded contract was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation, reflecting open competition among qualified...
- The Defense Logistics Agency has awarded a delivery order valued at $20,231.75 to AmerisourceBergen Drug Corp for the supply of 1,440 units/mL of HAVRIX vaccine in syringe form. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, awarded on August 4, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,136.36 for 1,440 units/mL of HAVRIX vaccine syringes on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a single transaction under the company's larger pharmaceutical supply relationship...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for HAVRIX 1440 UN 1ML vaccines on August 11, 2025, with a ceiling value of $9,483.80 and an ultimate completion date of September 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,024.40 to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes on August 19, 2025, with ultimate completion by August 20, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine commonly used across military and federal healthcare systems for disease prevention and immunization...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Havrix 720 Unit/0.5 ML syringes, with a contract ceiling value of $2,268.96 and an ultimate completion date of August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was awarded through open competition. The place of performance is listed as Conshohocken, Pennsylvania, which is also the headquarters location of the prime...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Havrix 720 Unit/0.5 ML syringes, with a ceiling value of $1,012.20 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under the company's larger...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2LLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,508.18 to AmerisourceBergen Drug Corp for 1,440 units/mL of HAVRIX vaccine in syringe form. This competitively awarded, firm fixed-price delivery order was finalized on August 27, 2025, with an ultimate completion date of August 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified pharmaceutical distributors. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a leading pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp supplies critical medical commodities including vaccines, medications, and medical supplies to support military healthcare programs globally. The IDC vehicle enables the company to serve the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems, positioning HAVRIX vaccine procurement within the broader context of the company's comprehensive pharmaceutical support mission for the Department of Defense.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.5k | 8/27/25 |